---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002694"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:30:18.620290+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure reports FY2022 net loss of $74.7M; cash $159.9M, runway into mid-2025

## Summary
- Net loss of $74.7M for FY2022 vs $69.4M in FY2021, driven by higher R&D expenses.
- Cash, equivalents, and marketable securities $159.9M at Dec 31, 2022, down from $219.6M.
- R&D expenses $54.2M (FY2022) vs $50.2M (FY2021); G&A $21.7M vs $20.6M.
- NC410 Phase 1b/2 combo with pembrolizumab update expected mid-2023; NC762 update Q4 2023.
- NC525 dosed first patient in Phase 1 AML trial Feb 2023; initial data expected Q4 2023.

## SEC filing metadata
- accession: 0001558370-23-002694
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837023002694/0001558370-23-002694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837023002694/nxtc-20230302x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002694
- JSON: https://secwatch.observer/filing/0001558370-23-002694.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.